MedTrace Logo

A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency Anemia

NCT03399084 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2019-05-30

No results posted yet for this study

Summary

This study will evaluate bioequivalence of two formulations of Ferric Carboxymaltose as measured by serum total iron, in adult patients with iron deficiency anemia.

Conditions

Interventions

DRUG

Ferric carboxymaltose

750 mg/15 mL

Sponsors & Collaborators

Principal Investigators

  • Sandoz Sandoz · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-29
Primary Completion
2019-01-15
Completion
2019-01-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03399084 on ClinicalTrials.gov